ISSN : 0376-4672
Purpose: The purpose of this study is to identify the effect of zoledronate(Zometa®), which is most common nitrogen containing bisphosphonate, on survival, proliferation, and differentiation of osteoblast. Material & Methods: Twenty four cell culture plates containing essential medium were seeded with UMR-106 cell lines, at density of 5 x 104 cells per plates. Each plates were incubated with 5% CO2 incubator at 37℃. Starting from 2 days after incubation, cell culture medias were replaced, and added with osteogenesis induction media and 0, 0.01, 0.1, 0.5, 1, 3μM of zoledronate(Zometa®), every 2 days, for 12 days. “Control group” was plates not added with zoledronate(0μM), and “experiment group” were plates added with different concentration of zoledronates(0, 0.01, 0.1, 0.5, 1, 3μM). Mature osteoblasts were identified with Alizarine Red staining, and protein samples were collected. Optical density was determined at wavelength of 405nm with ELISA reader. For viability analysis, cells were harvested and incubated with propidium iodide, and analysed with flow cytometry. Western blot technique was used to analyse Runx2 protein of osteoblast. Results: Secretion of bone matrix decreased as zoledronate concentration increased, and zoledronate did not effect survival rate of UMR-106 cells when measured with flow cytometer. Expression of Runx2 protein was inhibited as zoledronate concentration increased. Conclusion: From the results, we were able to identify that increase of zoledronate concentration inhibited differentiation of UMR-106 cell to osteoblast, without effecting quantity or survival rate.
1. Menschutkin M. Ueber die Einwirkung des Chloracetyls auf phophorige Saure. Ann Chem Pharm 1865:133:317-320. cited from 2.
2. Fleisch H, Russell RGG, Bisaz S, Casey PA, Muhlbauer RC. The influence of pyrophosphate analogues(diphosphates) on the precipitation and dissolution. Calcif Tissue Res 1968:suppl:10-10a.
3. Smith R, Russell RGG, Bishop MC, Woods CG, Bishop M. Paget’s disease of bone, Experience with a disphosphonate(disodium etidronate) in treatment. Q J Med 1973:42:235-256.
4. Russell RGG, Preston C, Walton J, et al. Disphosphonates in Paget’s disease. Lancet 1974:1(7863):894-898.
5. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 4th ed. San Diego, CA: Academic Press: 2000.
6. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998:19:80-100.
7. Reid IR, Brown JP, Burkhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Stat D, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002:346:653-661.
8. Reid IR. Zoledronate: efficacy and safe. J Bone Miner Res 2006:21:83-87.
9. Marx RE. Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003:61(9):1115-1117.
10. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006:35(7):588-593.
11. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004:62(5):527-534.
12. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphophonate-assosiated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005:104:83-93.
13. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment. Lancet Oncol 2006:7(6):508-514.
14. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006:144:753-761.
15. 권용대, 윤병욱, Christian W. Bisphosphonate, 구강악안면외과 영역의 새로운 위험 요소인가? 대한악안면성형재건외과학회지 2007:29(5):456-462.
16. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005:23 Suppl:36-42.
17. Goodship AE, Wallker PC, McNally D, Chambers T, Green JR. Use of a bisphosphonate(pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994:5 Suppl 7:S53-55.
18. Garcia-Moreno C, Serrano S, Nacher M, Farre, M, Diez A, Marinvoso ML, Carbonell J, Mellibovsky L, Nogues X, Ballester J, Aubia J. Effect of alendronate on cultured normal human osteoblasts. Bone 1998: 22(3): 233-239.
19. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranygeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999:96(1):133-138.
20. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000:141:4793-4796.
21. Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000:15(8):1467-1476.
22. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000:88(12 Suppl):2961- 2978.
23. Coxon FP, Rogers MJ. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function, Calcif Tissue Int 2003:72(1):80-84.
24. Martin TJ, Ingleton PM, Couton LA, Melick RA. Metabolic properties of hormonally responsive osteogenic sarcoma cells. Clin Orthop Relat Res 1979:(140):247-254.
25. Preston SJ, Laurent MR, Clifton-Blidgh P, Laurent MR, Jackson C, Mason RS. Effect of methotrexate and sulphasalazine on UMR-106 rat osteosarcoma cells. Br J Rheumatol 1997:36(2):178-184.
26. Body JJ, Sternon J. Treatment of Paget’s disease of bone with zoledronic acid. Rev Med Brux 2005:26(6):513-517.
27. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000:88(1):6-14.
28. Brenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001:91(10):1956.
29. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issue in Women With Breast Cancer. J Clin Oncol 2003:21(21):4042-4057.
30. Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 2005:17(5):555-559.
31. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 2005:12(4)1051-1058.
32. Wood J, Bonjean K, Stephan R, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002:302(3):1055-1061.
33. Santini D, Gentilucci UV, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003:14:1468-1476.
34. Rodan GA, Fleisch HA. Bisphosphonates mechanisms of action. J Clin Invest 1996:97(12):2692-2696.
35. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTPbinding proteins, including Ras. J Bone Miner Res 1998:13(4):581-589.
36. Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, Burr DB. Effects of highdose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fracture. Bone 2001:29(3):271-278.
37. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003:349(5):457-463.
38. Odvina CV, Zwewekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005:90(3):1294- 1301.
39. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008:Jun(3):[Epub ahead of print].
40. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007:5(10)475-482.
41. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology 2006:20(9):1053-1062.
42. Pazianas M, Miller P, Blumentals WA, Bernal M, kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007:29(8):1548-1558.
43. Cafro AM. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 2008:8(2):111-116.
44. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008:23(6):826-836.
45. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE. Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw. J Rhematol 2008:Jun(1):[Epub ahead of print].
46. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, & Gene Expression in Human Osteobasts. Cancer Res 2000:60(21):6001-6007.
47. Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A. Zoledronic acid upregulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 2004:384(3):591-598.
48. Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008:May(24):[Epub ahead of print].
49. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006:99(5):1233-1239.
